Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering

Stephanie H. Wilson, Robert D. Simari, Patricia Best, Tim E. Peterson, Lilach O Lerman, Michael Aviram, Karl A Nath, David Holmes, Amir Lerman

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Recent evidence suggests that some benefit from the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors may occur independent of lipid lowering. We aimed to determine the effect of simvastatin on coronary endothelial function, endothelial NO synthase (eNOS) expression and oxidative stress in experimental hypercholesterolemia (HC) in the absence of cholesterol lowering. Pigs were randomized to 3 experimental groups: Normal diet (N group), high cholesterol diet (HC group), and HC diet with simvastatin (HC+S group) for 12 weeks. Low density lipoprotein cholesterol was similarly increased in the HC and HC+S groups compared with the N group. In vitro analysis of coronary large- and small-vessel endothelium-dependent vasorelaxation was performed. The mean vasorelaxation of epicardial vessels to bradykinin was significantly attenuated in the HC group compared with the N group (32.3±1.2% versus 42.9±1.6%, respectively; P<0.0001). This attenuation was significantly reversed in the HC+S group (38.7±1.5%, P<0.005 versus HC group). The maximal vasorelaxation to substance P was significantly attenuated in the HC group compared with the N group (50.5±11.9% versus 79.3±5.3%, respectively; P<0.05). This attenuated response was normalized in the HC+S group (74.9±4.1%, P<0.05 versus HC group). The maximal arteriolar vasorelaxation to bradykinin was also significantly attenuated in the HC group compared with the N group (71.9±4.9% versus 96.8±1.34%, respectively; P<0.005). This was reversed in the HC+S group (98.4±0.6%, P<0.0001 versus HC group). Western blotting of coronary tissue homogenates for eNOS demonstrated a decrease in protein levels in the HC group compared with the N group, with normalization in the HC+S group. Elevation of plasma F2-isoprostanes and thiobarbituric acid-reactive substances, markers of oxidative stress, occurred in the HC compared with the N group. These changes were reversed in the HC+S group. In summary, simvastatin preserves endothelial function in coronary epicardial vessels and arterioles in experimental HC (in the absence of cholesterol lowering) in association with an increase in coronary eNOS levels and a decrease in oxidative stress. These alterations may play a role in the reduction in cardiac events after treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Original languageEnglish (US)
Pages (from-to)122-128
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume21
Issue number1
StatePublished - 2001

Fingerprint

Simvastatin
Hypercholesterolemia
Lipids
Vasodilation
Nitric Oxide Synthase
Oxidative Stress
Cholesterol
Bradykinin
Diet
Oxidoreductases
F2-Isoprostanes

Keywords

  • Endothelial NO synthase
  • Hypercholesterolemia
  • Nitric oxide
  • Vasorelaxation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. / Wilson, Stephanie H.; Simari, Robert D.; Best, Patricia; Peterson, Tim E.; Lerman, Lilach O; Aviram, Michael; Nath, Karl A; Holmes, David; Lerman, Amir.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 21, No. 1, 2001, p. 122-128.

Research output: Contribution to journalArticle

@article{66920cea16b3495681c42af07c407520,
title = "Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering",
abstract = "Recent evidence suggests that some benefit from the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors may occur independent of lipid lowering. We aimed to determine the effect of simvastatin on coronary endothelial function, endothelial NO synthase (eNOS) expression and oxidative stress in experimental hypercholesterolemia (HC) in the absence of cholesterol lowering. Pigs were randomized to 3 experimental groups: Normal diet (N group), high cholesterol diet (HC group), and HC diet with simvastatin (HC+S group) for 12 weeks. Low density lipoprotein cholesterol was similarly increased in the HC and HC+S groups compared with the N group. In vitro analysis of coronary large- and small-vessel endothelium-dependent vasorelaxation was performed. The mean vasorelaxation of epicardial vessels to bradykinin was significantly attenuated in the HC group compared with the N group (32.3±1.2{\%} versus 42.9±1.6{\%}, respectively; P<0.0001). This attenuation was significantly reversed in the HC+S group (38.7±1.5{\%}, P<0.005 versus HC group). The maximal vasorelaxation to substance P was significantly attenuated in the HC group compared with the N group (50.5±11.9{\%} versus 79.3±5.3{\%}, respectively; P<0.05). This attenuated response was normalized in the HC+S group (74.9±4.1{\%}, P<0.05 versus HC group). The maximal arteriolar vasorelaxation to bradykinin was also significantly attenuated in the HC group compared with the N group (71.9±4.9{\%} versus 96.8±1.34{\%}, respectively; P<0.005). This was reversed in the HC+S group (98.4±0.6{\%}, P<0.0001 versus HC group). Western blotting of coronary tissue homogenates for eNOS demonstrated a decrease in protein levels in the HC group compared with the N group, with normalization in the HC+S group. Elevation of plasma F2-isoprostanes and thiobarbituric acid-reactive substances, markers of oxidative stress, occurred in the HC compared with the N group. These changes were reversed in the HC+S group. In summary, simvastatin preserves endothelial function in coronary epicardial vessels and arterioles in experimental HC (in the absence of cholesterol lowering) in association with an increase in coronary eNOS levels and a decrease in oxidative stress. These alterations may play a role in the reduction in cardiac events after treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.",
keywords = "Endothelial NO synthase, Hypercholesterolemia, Nitric oxide, Vasorelaxation",
author = "Wilson, {Stephanie H.} and Simari, {Robert D.} and Patricia Best and Peterson, {Tim E.} and Lerman, {Lilach O} and Michael Aviram and Nath, {Karl A} and David Holmes and Amir Lerman",
year = "2001",
language = "English (US)",
volume = "21",
pages = "122--128",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering

AU - Wilson, Stephanie H.

AU - Simari, Robert D.

AU - Best, Patricia

AU - Peterson, Tim E.

AU - Lerman, Lilach O

AU - Aviram, Michael

AU - Nath, Karl A

AU - Holmes, David

AU - Lerman, Amir

PY - 2001

Y1 - 2001

N2 - Recent evidence suggests that some benefit from the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors may occur independent of lipid lowering. We aimed to determine the effect of simvastatin on coronary endothelial function, endothelial NO synthase (eNOS) expression and oxidative stress in experimental hypercholesterolemia (HC) in the absence of cholesterol lowering. Pigs were randomized to 3 experimental groups: Normal diet (N group), high cholesterol diet (HC group), and HC diet with simvastatin (HC+S group) for 12 weeks. Low density lipoprotein cholesterol was similarly increased in the HC and HC+S groups compared with the N group. In vitro analysis of coronary large- and small-vessel endothelium-dependent vasorelaxation was performed. The mean vasorelaxation of epicardial vessels to bradykinin was significantly attenuated in the HC group compared with the N group (32.3±1.2% versus 42.9±1.6%, respectively; P<0.0001). This attenuation was significantly reversed in the HC+S group (38.7±1.5%, P<0.005 versus HC group). The maximal vasorelaxation to substance P was significantly attenuated in the HC group compared with the N group (50.5±11.9% versus 79.3±5.3%, respectively; P<0.05). This attenuated response was normalized in the HC+S group (74.9±4.1%, P<0.05 versus HC group). The maximal arteriolar vasorelaxation to bradykinin was also significantly attenuated in the HC group compared with the N group (71.9±4.9% versus 96.8±1.34%, respectively; P<0.005). This was reversed in the HC+S group (98.4±0.6%, P<0.0001 versus HC group). Western blotting of coronary tissue homogenates for eNOS demonstrated a decrease in protein levels in the HC group compared with the N group, with normalization in the HC+S group. Elevation of plasma F2-isoprostanes and thiobarbituric acid-reactive substances, markers of oxidative stress, occurred in the HC compared with the N group. These changes were reversed in the HC+S group. In summary, simvastatin preserves endothelial function in coronary epicardial vessels and arterioles in experimental HC (in the absence of cholesterol lowering) in association with an increase in coronary eNOS levels and a decrease in oxidative stress. These alterations may play a role in the reduction in cardiac events after treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

AB - Recent evidence suggests that some benefit from the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors may occur independent of lipid lowering. We aimed to determine the effect of simvastatin on coronary endothelial function, endothelial NO synthase (eNOS) expression and oxidative stress in experimental hypercholesterolemia (HC) in the absence of cholesterol lowering. Pigs were randomized to 3 experimental groups: Normal diet (N group), high cholesterol diet (HC group), and HC diet with simvastatin (HC+S group) for 12 weeks. Low density lipoprotein cholesterol was similarly increased in the HC and HC+S groups compared with the N group. In vitro analysis of coronary large- and small-vessel endothelium-dependent vasorelaxation was performed. The mean vasorelaxation of epicardial vessels to bradykinin was significantly attenuated in the HC group compared with the N group (32.3±1.2% versus 42.9±1.6%, respectively; P<0.0001). This attenuation was significantly reversed in the HC+S group (38.7±1.5%, P<0.005 versus HC group). The maximal vasorelaxation to substance P was significantly attenuated in the HC group compared with the N group (50.5±11.9% versus 79.3±5.3%, respectively; P<0.05). This attenuated response was normalized in the HC+S group (74.9±4.1%, P<0.05 versus HC group). The maximal arteriolar vasorelaxation to bradykinin was also significantly attenuated in the HC group compared with the N group (71.9±4.9% versus 96.8±1.34%, respectively; P<0.005). This was reversed in the HC+S group (98.4±0.6%, P<0.0001 versus HC group). Western blotting of coronary tissue homogenates for eNOS demonstrated a decrease in protein levels in the HC group compared with the N group, with normalization in the HC+S group. Elevation of plasma F2-isoprostanes and thiobarbituric acid-reactive substances, markers of oxidative stress, occurred in the HC compared with the N group. These changes were reversed in the HC+S group. In summary, simvastatin preserves endothelial function in coronary epicardial vessels and arterioles in experimental HC (in the absence of cholesterol lowering) in association with an increase in coronary eNOS levels and a decrease in oxidative stress. These alterations may play a role in the reduction in cardiac events after treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

KW - Endothelial NO synthase

KW - Hypercholesterolemia

KW - Nitric oxide

KW - Vasorelaxation

UR - http://www.scopus.com/inward/record.url?scp=0035162842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035162842&partnerID=8YFLogxK

M3 - Article

C2 - 11145943

AN - SCOPUS:0035162842

VL - 21

SP - 122

EP - 128

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 1

ER -